2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, LGL, Hodgkin Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4327 A human multi-organoid platform temporally resolves immune cell trafficking across a cardiac-bone marrow axis

Jasmeet S. Reyat, PhD, Yuqi Shen, PhD2, Julie Rayes3, Abdullah Khan, PhD4
1 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
2 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
3 University of Birmingham, Birmingham, United Kingdom
4 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

Introduction. Innate immune cells serve as critical mediators of ischemic cardiac injury, driving regeneration and repair following infarct. Long term outcomes are known to be affected by a poorly understood but persistent remodelling of the bone marrow mediated by crosstalk between the injured cardiac tissue and the bone marrow. Recently, ischemic injury has been linked to an inflammatory, myeloid biased wave of emergency haematopoiesis driven by reprogramming of the haematopoietic stem cell compartment. The mechanism mediating this remodelling of the bone marrow remains difficult to dissect, largely due to the lack of human models that enable the resolution of both immune cell recruitment dynamics within injured cardiac tissue and across both the heart and bone marrow following injury.

Methods. To address this, we coupled a combined human bone marrow organoid (comBO) to a vascularised cardiac organoid (VCO) using a 3D-printed fluidic device. Ischaemic injury was induced by incubating the VCO in hypoxic conditions, and the cardiac compartment was harvested at baseline, 6 h and 48 h post-injury for single-cell RNA-sequencing. Cell-type composition and per-lineage transcriptional responses were quantified relative to baseline, with pathway activity assessed by pre-ranked fGSEA (MSigDB Hallmark and Reactome).

Results. Single-cell profiling captured a myeloid-dominated immune infiltrate (neutrophils, macrophages and mast cells) within the injured VCOs and resolved a two-phase acute response. At 6 h, both neutrophils and macrophages mounted a coordinated hypoxic–glycolytic programme (neutrophil HALLMARK_HYPOXIA normalised enrichment score [NES] 1.78, adjusted p = 6×10??; GLYCOLYSIS NES 1.76; macrophage HYPOXIA NES 1.84, adjusted p = 1×10??), inducing HIF-target and glycolytic genes (HILPDA, SLC2A1/GLUT1, HK2, EGLN3, BNIP3, NDRG1) and confirming faithful modelling of ischaemic injury. By 48 h this matured into neutrophil-dominated inflammatory activation: neutrophils became the principal granulocyte (13.4% of recovered cells versus 7.8% at baseline) and up-regulated TNF-α/NF-κB signalling (HALLMARK NES 1.67, adjusted p = 0.01) with the activation antigen CD69, the integrin CD11b (ITGAM), and the ROS-generating NADPH-oxidase subunit NCF2 (log2FC 1.25, adjusted p = 9×10?¹6). Critically, these hyperactivated neutrophils up-regulated CXCR4 (log2FC up to 1.4, adjusted p < 10?³) the chemokine receptor that directs neutrophil return to the bone marrow along the CXCL12 gradient. We therefore nominate a hyperactivated, marrow-homing neutrophil as a candidate carrier of injury signals to the marrow, and a plausible driver of the myeloid-biased remodelling we are actively investigating in the coupled comBO compartment.

Conclusions. This multi-organoid platform accesses the acute, hours-scale phase of cardiac ischaemic injury that is largely unobservable in patients, resolving a hypoxic-metabolic response that matures into neutrophil hyperactivation. By capturing hyperactivated, CXCR4-high neutrophils it nominates neutrophil retrograde trafficking to the marrow as a mechanistic link to bone marrow remodelling and hyper-myeloid output, and provides a controlled human system to dissect the cardiac–marrow axis that confounded patient cohorts cannot resolve.

Jasmeet S. Reyat, PhD: No relevant conflicts of interest to declare.